@article{7db732c209c64a6093ae255d1a7cb28d,
title = "Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes",
abstract = "Chronic hepatitis C virus (HCV) is a risk factor for type 2 diabetes. In the era of interferon-based HCV therapy, type 2 diabetes was associated with decreased likelihood of sustained virologic response (SVR). Preliminary studies suggest that type 2 diabetes may not reduce the efficacy of regimens involving direct-acting antiviral (DAA) medications. We aimed to determine whether preexisting type 2 diabetes is associated with a reduced rate of SVR achieved 12 weeks after treatment of HCV with DAA-based regimens.",
author = "Niccum, {Blake A.} and Stine, {Jonathan G.} and Wynter, {Javelle A.} and Virginia Kelly and Caldwell, {Stephen H.} and Shah, {Neeral L.}",
note = "Funding Information: J.G.S. has received research funding from Bayer and Target PharmaSolutions. S.H.C. has received research funding from Conatus Pharmaceuticals, Galmed Pharmaceuticals, Genfit, Gilead Sciences, Mallinckrodt Pharmaceuticals, NGM Bio-pharmaceuticals, and Vital Therapies. He has also received patent royalties from Halyard Health. No other potential conflicts of interest relevant to this article were reported. Publisher Copyright: {\textcopyright} 2019 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.",
year = "2021",
month = jan,
doi = "10.2337/cd18-0112",
language = "English (US)",
volume = "38",
pages = "40--46",
journal = "Clinical Diabetes",
issn = "0891-8929",
publisher = "American Diabetes Association Inc.",
number = "1",
}
